Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Radiation drives the evolution of orthotopic xenografts initiated from glioblastoma stem-like cells.

McAbee JH, Rath BH, Valdez K, Young DL, Wu X, Shankavaram UT, Camphausen K, Tofilon PJ.

Cancer Res. 2019 Oct 15. pii: canres.2452.2019. doi: 10.1158/0008-5472.CAN-19-2452. [Epub ahead of print]

PMID:
31615806
2.

Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.

Krauze AV, Mackey M, Rowe L, Chang MG, Holdford DJ, Cooley T, Shih J, Tofilon PJ, Camphausen K.

Neurooncol Pract. 2018 Nov;5(4):246-250. doi: 10.1093/nop/npy009. Epub 2018 Apr 16.

PMID:
30402263
3.

The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo.

Wahba A, Rath BH, O'Neill JW, Camphausen K, Tofilon PJ.

Mol Cancer Ther. 2018 Aug;17(8):1717-1726. doi: 10.1158/1535-7163.MCT-17-1303. Epub 2018 Jun 4.

4.

The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts.

Timme CR, Rath BH, O'Neill JW, Camphausen K, Tofilon PJ.

Mol Cancer Ther. 2018 Jun;17(6):1207-1216. doi: 10.1158/1535-7163.MCT-17-1267. Epub 2018 Mar 16.

5.

Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity.

Rath BH, Waung I, Camphausen K, Tofilon PJ.

Mol Cancer Ther. 2018 May;17(5):1070-1078. doi: 10.1158/1535-7163.MCT-17-1053. Epub 2018 Feb 26.

6.

Radiation-induced alternative transcripts as detected in total and polysome-bound mRNA.

Wahba A, Ryan MC, Shankavaram UT, Camphausen K, Tofilon PJ.

Oncotarget. 2017 Oct 9;9(1):691-705. doi: 10.18632/oncotarget.21672. eCollection 2018 Jan 2.

7.

Radiation-induced translational control of gene expression.

Wahba A, Lehman SL, Tofilon PJ.

Translation (Austin). 2016 Dec 1;5(1):e1265703. doi: 10.1080/21690731.2016.1265703. eCollection 2017. Review.

8.

FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells.

Maachani UB, Shankavaram U, Kramp T, Tofilon PJ, Camphausen K, Tandle AT.

Oncotarget. 2016 Nov 22;7(47):77365-77377. doi: 10.18632/oncotarget.12670.

9.

Polysome Profiling Links Translational Control to the Radioresponse of Glioblastoma Stem-like Cells.

Wahba A, Rath BH, Bisht K, Camphausen K, Tofilon PJ.

Cancer Res. 2016 May 15;76(10):3078-87. doi: 10.1158/0008-5472.CAN-15-3050. Epub 2016 Mar 22.

10.

Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization.

Rath BH, Wahba A, Camphausen K, Tofilon PJ.

Cancer Med. 2015 Nov;4(11):1705-16. doi: 10.1002/cam4.510. Epub 2015 Oct 30.

11.

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.

Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992. doi: 10.1016/j.ijrobp.2015.04.038. Epub 2015 Apr 30.

12.

Ionizing radiation and glioblastoma exosomes: implications in tumor biology and cell migration.

Arscott WT, Tandle AT, Zhao S, Shabason JE, Gordon IK, Schlaff CD, Zhang G, Tofilon PJ, Camphausen KA.

Transl Oncol. 2013 Dec 1;6(6):638-48. eCollection 2013 Dec 1.

13.

The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K, Tofilon PJ.

Neuro Oncol. 2014 Jan;16(1):29-37. doi: 10.1093/neuonc/not139. Epub 2013 Dec 4.

14.

The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.

Hayman TJ, Wahba A, Rath BH, Bae H, Kramp T, Shankavaram UT, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2014 Jan 1;20(1):110-9. doi: 10.1158/1078-0432.CCR-13-2136. Epub 2013 Nov 6.

15.

Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.

Eur J Cancer. 2013 Sep;49(14):3020-8. doi: 10.1016/j.ejca.2013.05.013. Epub 2013 Jun 18.

16.

Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.

Hayman TJ, Kramp T, Kahn J, Jamal M, Camphausen K, Tofilon PJ.

Transl Oncol. 2013 Jun 1;6(3):355-62. Print 2013 Jun.

17.

Astrocytes enhance the invasion potential of glioblastoma stem-like cells.

Rath BH, Fair JM, Jamal M, Camphausen K, Tofilon PJ.

PLoS One. 2013;8(1):e54752. doi: 10.1371/journal.pone.0054752. Epub 2013 Jan 22.

18.

Preclinical models in radiation oncology.

Kahn J, Tofilon PJ, Camphausen K.

Radiat Oncol. 2012 Dec 27;7:223. doi: 10.1186/1748-717X-7-223. Review.

19.

The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells.

Jamal M, Rath BH, Tsang PS, Camphausen K, Tofilon PJ.

Neoplasia. 2012 Feb;14(2):150-8.

20.

Translation initiation factor eIF4E is a target for tumor cell radiosensitization.

Hayman TJ, Williams ES, Jamal M, Shankavaram UT, Camphausen K, Tofilon PJ.

Cancer Res. 2012 May 1;72(9):2362-72. doi: 10.1158/0008-5472.CAN-12-0329. Epub 2012 Mar 7.

21.

Post-radiation increase in VEGF enhances glioma cell motility in vitro.

Kil WJ, Tofilon PJ, Camphausen K.

Radiat Oncol. 2012 Feb 22;7:25. doi: 10.1186/1748-717X-7-25.

22.

Salen Mn complexes mitigate radiation injury in normal tissues.

Rosenthal RA, Fish B, Hill RP, Huffman KD, Lazarova Z, Mahmood J, Medhora M, Molthen R, Moulder JE, Sonis ST, Tofilon PJ, Doctrow SR.

Anticancer Agents Med Chem. 2011 May 1;11(4):359-72. Review.

23.

Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic.

Shabason JE, Tofilon PJ, Camphausen K.

J Cell Mol Med. 2011 Dec;15(12):2735-44. doi: 10.1111/j.1582-4934.2011.01296.x. Review.

24.

Microenvironmental regulation of glioblastoma radioresponse.

Jamal M, Rath BH, Williams ES, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2010 Dec 15;16(24):6049-59. doi: 10.1158/1078-0432.CCR-10-2435. Epub 2010 Oct 29. Erratum in: Clin Cancer Res. 2011 Apr 1;17(7):2068.

25.

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102.

Buchanan IM, Scott T, Tandle AT, Burgan WE, Burgess TL, Tofilon PJ, Camphausen K.

J Cell Mol Med. 2011 Sep;15(9):1999-2006. doi: 10.1111/j.1582-4934.2010.01122.x. Epub 2010 Jul 12.

26.

HDAC inhibitors in cancer care.

Shabason JE, Tofilon PJ, Camphausen K.

Oncology (Williston Park). 2010 Feb;24(2):180-5.

27.

Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat.

Kahali S, Sarcar B, Fang B, Williams ES, Koomen JM, Tofilon PJ, Chinnaiyan P.

Neoplasia. 2010 Jan;12(1):80-6.

28.

High throughput evaluation of gamma-H2AX.

Avondoglio D, Scott T, Kil WJ, Sproull M, Tofilon PJ, Camphausen K.

Radiat Oncol. 2009 Aug 24;4:31. doi: 10.1186/1748-717X-4-31.

29.

CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines.

McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2009 Aug 15;15(16):5145-53. doi: 10.1158/1078-0432.CCR-09-0263. Epub 2009 Aug 11.

30.

Urine analysis and protein networking identify met as a marker of metastatic prostate cancer.

Russo AL, Jedlicka K, Wernick M, McNally D, Kirk M, Sproull M, Smith S, Shankavaram U, Kaushal A, Figg WD, Dahut W, Citrin D, Bottaro DP, Albert PS, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2009 Jul 1;15(13):4292-8. doi: 10.1158/1078-0432.CCR-09-0599. Epub 2009 Jun 23.

31.

Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.

McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ.

Mol Cancer Res. 2009 Apr;7(4):489-97. doi: 10.1158/1541-7786.MCR-08-0360. Erratum in: Mol Cancer Res. 2009 Jun;7(6):987. Shankavarum, Uma T [corrected to Shankavaram, Uma T].

32.

Molecular targets for tumor radiosensitization.

Tofilon PJ, Camphausen K.

Chem Rev. 2009 Jul;109(7):2974-88. doi: 10.1021/cr800504x. Review. No abstract available.

33.

In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.

Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2009 Jan 15;15(2):607-12. doi: 10.1158/1078-0432.CCR-08-2079.

34.

The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.

Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W Jr, Mehta MP.

Radiat Oncol. 2008 Sep 25;3:32. doi: 10.1186/1748-717X-3-32.

35.

Postradiation sensitization of the histone deacetylase inhibitor valproic acid.

Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2008 Sep 1;14(17):5410-5. doi: 10.1158/1078-0432.CCR-08-0643.

36.

Radiation-induced gene translation profiles reveal tumor type and cancer-specific components.

Kumaraswamy S, Chinnaiyan P, Shankavaram UT, Lü X, Camphausen K, Tofilon PJ.

Cancer Res. 2008 May 15;68(10):3819-26. doi: 10.1158/0008-5472.CAN-08-0016.

37.

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.

Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K.

Clin Cancer Res. 2008 Feb 1;14(3):931-8. doi: 10.1158/1078-0432.CCR-07-1856.

38.

Inhibition of histone deacetylation: a strategy for tumor radiosensitization.

Camphausen K, Tofilon PJ.

J Clin Oncol. 2007 Sep 10;25(26):4051-6. Review.

PMID:
17827453
39.

Inhibition of Hsp90: a multitarget approach to radiosensitization.

Camphausen K, Tofilon PJ.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4326-30. Review.

40.

Inhibition of hsp90 compromises the DNA damage response to radiation.

Dote H, Burgan WE, Camphausen K, Tofilon PJ.

Cancer Res. 2006 Sep 15;66(18):9211-20.

41.

Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.

de la Peña L, Burgan WE, Carter DJ, Hollingshead MG, Satyamitra M, Camphausen K, Tofilon PJ.

Mol Cancer Ther. 2006 Jun;5(6):1504-10.

42.

Histone deacetylation as a target for radiosensitization.

Cerna D, Camphausen K, Tofilon PJ.

Curr Top Dev Biol. 2006;73:173-204. Review.

PMID:
16782459
43.

In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).

Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2006 May 1;12(9):2912-8.

44.

Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes.

Lü X, de la Peña L, Barker C, Camphausen K, Tofilon PJ.

Cancer Res. 2006 Jan 15;66(2):1052-61.

45.

Orthotopic growth of human glioma cells quantitatively and qualitatively influences radiation-induced changes in gene expression.

Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ.

Cancer Res. 2005 Nov 15;65(22):10389-93.

46.

ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.

Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ.

Cancer Res. 2005 Aug 1;65(15):6967-75.

47.

Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.

Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2005 Jun 15;11(12):4571-9.

48.

Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions.

Camphausen K, Purow B, Sproull M, Scott T, Ozawa T, Deen DF, Tofilon PJ.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8287-92. Epub 2005 May 31.

49.

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.

Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, Oswald KA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2004 Dec 1;10(23):8077-84.

50.

Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.

Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ.

Int J Cancer. 2005 Apr 10;114(3):380-6.

Supplemental Content

Loading ...
Support Center